

To
The Honourable
Mr Adonis Georgiadis
Minister of Health

Cc.: Mr Nikos Choulis, Chairman of the Special Committee for the Preparation of the List
Mr Demetrios Kontos, President of EOPYY
Mr Christos Chalaris, Managing Director of HDIKA
Mr Demetrios Lintzeris, President of EOF
Mr Stavros Evangelatos, Head of the Directorate of Medicinal Products & Pharmacies

Chalandri, March 31, 2014

Subject: Problems in the revised Reimbursement list of prescribed medicinal products

Dear Minister,

Further to the publication dated 26/3/2014 of the reimbursement list of prescribed medicinal products (it is reminded that this is the third time the said list is revised, within almost one month due to errors), we would like to draw your attention on the following:

- There are products which, although the relevant entrance fee in the reimbursement list etc. has been paid, they have erroneously not been included in the reimbursement list.
- The methodology based on which the reference price of the clusters was calculated is not known. The companies, in order to be able to file any objections they may have, for which the relevant deadline expires on 2/4/2014 based on the relevant announcement of EOF, must be aware of all data based on which the Special Committee decided the classification of their products and the calculation of the reference price.

In addition, it is reminded that based on article 6 of the EC Directive 89/105, decisions that concern the reimbursement of the cost of the medicinal products must be justified and based on objective and verifiable criteria.

Taking into account the above and given the discomfort that the patients face for more than a month now, with the constant modifications of the list that obstruct access to their treatments, **we kindly request that you instruct HDIKA:**

- **To communicate to the pharmaceutical companies involved the data based on which the reference prices were calculated per therapeutic category (cluster).**
- **To notify to us the methodology for the calculation of the reference prices per therapeutic category (cluster), i.e. what average was applied, which is the market share of the three (3) cheapest generics or if the weighted average was used between originals and generics (and in which cases was it used).**
- **To send to SFEE, for the facilitation of its members, the reimbursement list in an electronic file that can be accessed and processed (excel).**

Yours sincerely

Konstantinos M. Frouzis
President

Paschalis Apostolidis
Vice President

280 Kifissias Avenue & 3 Agriniou St., 152 32 CHALANDRI, ATHENS
TEL. 210 6891101 – FAX 210 6891060

www.sf ee.gr